BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Łucejko M, Tomasiewicz K, Olczak A, Tudrujek-Zdunek M, Halota W, Jelski W, Donica H, Krintus M, Mroczko B, Flisiak R. Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals. Br J Biomed Sci 2019;76:190-4. [PMID: 31401936 DOI: 10.1080/09674845.2019.1654790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Blann A. British Journal of Biomedical Science in 2019. What have we learned? Br J Biomed Sci 2020;77:1-6. [PMID: 31818192 DOI: 10.1080/09674845.2019.1692455] [Reference Citation Analysis]
2 Flores GL, Mota JC, da Silva Andrade LT, Lopes RS, Bastos FI, Villar LM, Komatsu H. Performance of HCV Antigen Testing for the Diagnosis and Monitoring of Antiviral Treatment: A Systematic Review and Meta-Analysis. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/7348755] [Reference Citation Analysis]
3 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]